Franklin Resources BEN
Financial Services · Asset Management · Synthos Deep Dive · 2026-07-03
The Overview
Franklin Resources (brand name Franklin Templeton) is a company that manages other people's money — mutual funds, bond funds, and increasingly private/alternative funds — and earns a fee on the pile it manages (about $1.68 trillion). When the fee pile grows, Franklin earns more; when clients pull money out or markets fall, it earns less.
The problem: for years, investors have been moving money out of expensive "active" funds (where a manager picks stocks) into cheap "index" funds (which just track the market). Franklin is on the losing side of that shift. It has been fighting back by buying other firms and pushing into private/alternative funds, and this year clients finally stopped pulling money out — which is why the stock jumped 40%.
Is it cheap or expensive? On its adjusted earnings it looks cheap (about 12× earnings) and pays a nice 3.8% dividend. But it barely grows, and the stock has already run up to a one-year high, sitting slightly above what Wall Street analysts think it's worth. Our verdict is Watch — not a screaming buy, not an obvious sell.
What the three scores mean in everyday terms:
- Downside Risk 6/10 (a bit riskier than average). The stock is cheap, which helps, but it swings more than the market (high "beta"), profits have been shrinking, and its core business is under long-term pressure.
- Growth Quality 3/10 (weak). This is a mature business that grows slowly, and its profit margins have gone the wrong way.
- Exponential Potential 2/10 (very low). Don't expect this to multiply. The industry tide is against it; any AUM growth mostly comes from the stock market rising, not from Franklin winning lots of new money.
The one big worry: the money-management industry keeps shifting to cheap index funds, and Franklin's big bond unit (Western Asset) was hit by a regulatory investigation that drove clients away. If net withdrawals resume, both earnings and the stock can fall.
Putting a number on it: our fair-value estimate is $32 against a current price of $34.65 — a premium price for a business we still like.
Our summary metrics
Cheap on adjusted EPS (~12x) but beta 1.59, EV/EBITDA 16.7x on falling EBITDA, and a secular active-outflow threat.
Low-single-digit fwd EPS CAGR, margins compressed from 27% to 14% GAAP, ROE ~6.7% — a mature, challenged compounder.
Active asset manager losing share to passive/ETF; AUM growth is beta-driven, not organic — no exponential engine.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Active asset manager losing share to passive/ETF; AUM growth is beta-driven, not organic — no exponential engine.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $32.75 (high $34 / low $31; 6 Buy · 16 Hold · 5 Sell — consensus Hold) — context, not our anchor |
| Valuation | 25× trailing GAAP EPS · ~12× adjusted EPS · 12× FY26E · 11× FY27E · EV/S 3.3× · EV/EBITDA 16.7× |
| Technicals | Extended — $34.11 at the 52-wk high, RSI 70 (overbought), +40% 12-mo (SPY +21%), well above 50/200-DMA |
| Conviction | Low — 0 expert voices, 0 traceable claims in the KB; this is a screen/quant call |
| Position sizing | If owned at all: income/value satellite, ≤1–2%; not a core compounder |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for BEN — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $34.65, 3% above the 50-day average ($34), 23% above the 200-day average ($28) — an uptrend. 3% below the 52-week high of $36, 64% above the 52-week low of $21.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $34.65 is currently inside the band (band $33–$36).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 57.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.05, positive momentum.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = BEN · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Franklin Resources, Inc. (NYSE: BEN, operating as Franklin Templeton) is a ~$17.7B global investment manager founded in 1947, based in San Mateo, CA, led by CEO Jennifer ("Jenny") Johnson (a member of the founding Johnson family, which retains large ownership). It manages $1,682 billion of AUM (as of 31-Mar-2026) across equity, fixed income, multi-asset, and — increasingly — alternatives/private markets (via affiliates like Benefit Street Partners, Clarion, Lexington, and the specialist investment managers acquired with Legg Mason in 2020, including Western Asset Management). Fiscal year ends September 30.
The economics are simple and beta-linked: Franklin earns investment management fees as a percentage of AUM, plus sales/distribution and shareholder-servicing fees. When AUM rises (markets up or net inflows), revenue rises; when clients redeem (as they did heavily at Western Asset), revenue falls.
Revenue mix (FY2025, from filings):
- By type (product): Investment advisory/management & admin $6.98B (80%) · Sales & distribution fees $1.47B (17%) · Shareholder servicing $0.26B · Other $0.05B.
- By geography: United States $6.61B (~75%) · Luxembourg (the cross-border fund domicile) $1.30B · Asia-Pacific $0.33B · EMEA ex-Lux $0.28B · Americas ex-US $0.25B. Heavily US-weighted, with the Luxembourg line representing the European fund-distribution hub.
The strategic pivot management keeps emphasizing: (a) scale alternatives / private markets (fundraised $14.3B in alternatives in Q2 FY26, $22.7B fiscal YTD), and (b) grow ETFs and Canvas (custom-indexing / direct-indexing), both of which reached record AUM — i.e. trying to migrate a legacy active book toward the products that are actually taking in money.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of BEN in the Synthos knowledge base. total_claims = 0; there are zero net-bullish and zero cautionary voices distilled for this name. We will not manufacture a "panel." This verdict is entirely fundamentals- and quant-driven, and readers should weight it accordingly: unlike a conviction-track name (where independent expert claims corroborate the numbers), here you are getting Synthos's own read of the filings, estimates, and price action — nothing more, nothing less.
Because there are no claim_ids to cite, §2 carries no citations by design. Every number elsewhere in this note traces to the FMP financials, the SEC 8-K earnings release, or the live estimates pull (see Provenance).
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Moderate-High | Valuation is a cushion (~12× adjusted EPS, 3.8% yield), but beta 1.59 (swings far more than the market), EV/EBITDA 16.7× on falling EBITDA, GAAP net-debt/EBITDA optically ~6.7× (inflated by consolidated investment products), and a genuine secular threat. Cheap does not mean safe here. |
| Growth Quality | 3 · Weak | Forward EPS CAGR only ~low-single-digits (FY26E $2.76 → FY29E $3.57 ≈ 9%/yr off a depressed base), GAAP operating margin collapsed from ~27% (FY21) to ~7–14% recently, ROE ~6.7%, ROIC ~1.9%. A mature, structurally pressured book. |
| Exponential Potential | 2 · Low | Active management is ceding share to passive/ETF; AUM gains are mostly market beta, not durable organic wins. The alternatives/ETF pivot is real but not yet needle-moving at $1.68T scale. No acceleration engine. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. We value BEN on adjusted EPS (the market's yardstick for asset managers, since GAAP is distorted by intangible amortization, impairments, and consolidated-investment-product noise); adjusted EPS is running ~$0.70/qtr ≈ $2.80 annualized.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Positive long-term net inflows persist across regions; alternatives + ETF/Canvas scale and lift the fee rate; markets stay firm; adjusted EPS reaches ~$3.20; multiple re-rates to ~13× as the "active manager in secular decline" discount narrows. | ~$42 (+23%) |
| Base (our anchor) | Flows roughly neutral-to-slightly-positive; AUM drifts up with markets; adjusted EPS ~$2.90; the stock holds a mid-cycle ~11× adjusted multiple appropriate for a low-growth, high-payout manager. | ~$32 (−6%) |
| Bear | Western Asset / active redemptions resume, or a market drawdown shrinks the fee base; adjusted EPS slips to ~$2.30; multiple de-rates to ~9× as the secular-decline narrative reasserts. | ~$21 (−38%) |
Synthos fair value = the base case, ~$32 (−6%), with the full $21–$42 span as the honest range. This sits essentially on top of the Street's $32.75 consensus and below today's $34.11 price — i.e. after a 40% run, the stock has closed the gap to fair value and then some. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). BEN is neither — it is a mature, cyclically-levered value/income name with a structural headwind:
- Forward growth: revenue is essentially flat-to-down on consensus (FY25 $8.77B → FY26E ~$7.0B → FY29E ~$8.5B; note the FMP estimate line uses a different revenue definition than the GAAP top line, but the shape is low-growth either way). Adjusted EPS grows ~high-single-digits off a depressed FY25 base, largely a recovery rather than secular expansion.
- Acceleration (2nd derivative): negative-to-flat. The AUM recovery to $1.68T is real but beta-driven; the underlying active book still bleeds share to passive. The one genuine bright spot — 19 consecutive quarters of positive multi-asset flows and record ETF/Canvas AUM — is not yet large enough to inflect the whole franchise.
- Room to run vs TAM: the global asset-management "TAM" is enormous, but Franklin is a share-loser inside it. TAM size is irrelevant when your product mix is on the wrong side of the flow. There is no small-cap-with-huge-market dynamic here.
- Reinvestment runway: capital is going to acquisitions and dividends, not organic-growth reinvestment with rising returns on capital (ROIC ~1.9%). That is capital return, not compounding.
Exponential Potential: Low (2/10). Own BEN — if at all — for yield and a cheap adjusted multiple, never for growth. A small, accelerating name would score 8–9; BEN is the opposite profile.
5. Financials (real numbers — FMP annual/quarterly + SEC 8-K)
- Revenue: FY25 (GAAP, ended 9/30/25) $8.77B, +3.5% (FY24 $8.48B; FY23 $7.85B). Growth is largely the full-year consolidation of acquisitions, not organic strength.
- AUM (the real driver): $1,682.1B at 31-Mar-2026, +9% YoY, roughly flat QoQ ($1,684B → $1,682B) as +$16.9B long-term net inflows were offset by −$30.2B of negative market change/distributions. Long-term net flows turned positive in the quarter — a meaningful stabilization vs the prior Western Asset redemption crisis.
- Margins (the ugly part): GAAP operating margin 14.1% in Q2 FY26 (up from 6.9% a year ago, but down from ~21–27% in FY21–22). Adjusted operating margin 27.1% in Q2 FY26 — the gap between the two is amortization of acquired intangibles, an intangible impairment, and consolidated-investment-product (CIP) noise. GAAP net margin TTM ~7.7%; adjusted is far higher.
- Earnings: GAAP net income attributable $471.7M FY25, EPS $0.91. But adjusted diluted EPS is running ~$0.70–$0.71/quarter (Q2 FY26 $0.71 vs $0.47 a year ago, +51%) ≈ ~$2.80 annualized — the number the market actually capitalizes. Q2 FY26 beat: $0.71 adj vs $0.55 Street.
- Cash flow: FY25 operating CF $1.07B, capex only −$0.15B, FCF ~$0.91B (FCF yield ~5.2%). FCF comfortably covers the $684M dividend — but the GAAP payout ratio is ~84%, high, and only looks safe because adjusted earnings are much larger than GAAP.
- Balance sheet: cash & investments ~$5.1B; total debt $13.3B, net debt ~$9.7B. Reported net-debt/EBITDA ~6.7× looks alarming but is inflated by CIP consolidation and low GAAP EBITDA; on EV/EBITDA the market pays 16.7×. Interest coverage ~9×. Investment-grade, serviceable — but leverage is not trivial and rose with the Legg Mason deal.
6. Valuation — priced in or room?
On the market's yardstick (adjusted EPS ~$2.80), BEN trades at ~12× trailing / ~12× FY26E / ~11× FY27E — genuinely cheap versus the market, and cheap versus higher-quality peers (T. Rowe ~13–15×, and the alternatives platforms Blackstone/Ares at 25–40×). Add a 3.8% dividend yield and the value case is clear. On GAAP the P/E is a misleading 25× (depressed by non-cash charges).
But cheap-for-a-reason: the low multiple is the market pricing the secular active-outflow risk and sub-7% ROE, not an inefficiency. A reverse read: today's $34.11 already capitalizes ~$2.90 of normalized adjusted EPS at ~11–12× — i.e. the market is giving Franklin credit for the flow stabilization. There is little further re-rating unless organic flows durably inflect.
Street targets (context): consensus $32.75, high $34, low $31 — the entire analyst range now sits at or below the current price, and the consensus rating is Hold (6 Buy / 16 Hold / 5 Sell). Our ~$32 base FV agrees with the Street: after the run, upside is limited and the risk skews to the downside case. Not a value trap to short, but not a fresh-money buy at $34.
7. Technicals (from the tech block)
- Trend: up, but extended. $34.11 sits above the 50-DMA ($31.36) and well above the 200-DMA ($26.13) (golden-cross posture). MACD +0.76 (positive).
- Location: exactly at the 52-week high ($34.11, 0.0% from high), +61% off the 52-week low ($21.18). Max drawdown from peak only −9.5% — a strong up-move with shallow pullbacks.
- Momentum: RSI(14) 70.0 — right at the overbought threshold. This is a stretched entry point; historically a poor place to initiate.
- Relative strength: BEN +40% 12-mo vs SPY +21% (and +44.6% 3-mo vs SPY +13.7%) — sharp recent outperformance, but it lagged QQQ over 12 months (QQQ +30%). The move is a recovery/re-rating, not sustained leadership.
- Read: technicals say do not chase here. A name at its 52-week high, at RSI 70, trading above the Street's highest price target, argues for patience — a pullback toward the rising 50-DMA (~$31) would be a far better risk/reward for anyone who wants the yield.
8. Moat & competitive position
Franklin's "moat" is distribution scale, brand, and switching-cost stickiness in a business where the product itself (active management) is being commoditized by passive/ETF. That is a weak moat trend: scale helps defend fees but does not stop share loss. The bright spots — alternatives/private markets (harder to index, higher fees, stickier) and ETF/Canvas custom indexing — are where Franklin is trying to rebuild a durable edge, and they are growing, but from a small base relative to the $1.68T whole.
The Western Asset Management episode (a regulatory investigation into a star fixed-income manager that triggered large institutional redemptions) is the clearest illustration of the fragility: key-person and reputational risk can vaporize AUM quickly in active management. Q2 FY26 still showed −$4.1B long-term net outflows at Western, even as the total firm turned net-positive.
Peer set (market cap): BlackRock $155B (the passive/ETF winner), Blackstone $96B and Ares $38B (the alternatives winners), Ameriprise $44B, State Street $47B, Northern Trust $33B, T. Rowe Price $25B (closest active-manager comp), Principal $24B, Invesco $12B, Affiliated Managers $9B, Janus Henderson $8B. The structural tell: the market caps reward the passive and alternatives players and penalize the legacy active managers (BEN, IVZ, JHG, TROW) — Franklin sits squarely in the penalized cohort.
9. Management, capital allocation & guidance
- Capital allocation: dividend-first ($684M FY25, 3.8% yield, ~84% GAAP payout), modest buybacks (2.3M shares for $57.1M in Q2 FY26), and M&A (Legg Mason and a string of alternatives/private-markets deals) to buy the growth the organic book can't generate. Reasonable for a mature manager, but the buyback is small and the payout leans on adjusted (not GAAP) earnings.
- Insider activity: the recent Form-4s are routine director stock/deferred-fee awards (e.g. Feb 2026 director grants at ~$27), not open-market conviction buys or alarming discretionary sales. Note the founding Johnson family remains a large long-term holder — an alignment positive. No red-flag insider selling in the sampled window.
- Management's own guidance (half-weighted — their own book): Franklin does not issue formal EPS/revenue guidance; the Q2 FY26 8-K (28-Apr-2026) is a results release, not a forward outlook. CEO Jenny Johnson's framing: "$17 billion in long-term net inflows across public and private markets… positive long-term net flows in every region… $14.3 billion in alternatives fundraising… ETFs and Canvas reached record AUM… we're pleased to be ahead of plan." That is a real, substantive flow update (not boilerplate), but it is management's self-interested characterization and carries no hard forward numbers — treat the tone as optimistic and the flows as the fact to verify each quarter. Formal forward guidance was not available.
10. Catalysts & what to watch
- Next earnings: 2026-07-31 (Q3 FY26; Street EPS $0.65). The key lines: long-term net flows by asset class/region and whether Western Asset outflows keep shrinking.
- Monthly AUM disclosures: Franklin reports AUM monthly — the fastest read on flows and market beta.
- Fee-rate trend: does the alternatives/ETF mix shift lift the effective fee rate, or does passive keep compressing it?
- Markets: as a high-beta (1.59) AUM-linked name, a broad equity/credit drawdown hits revenue directly — this is the single biggest swing factor.
- Alternatives fundraising: continued $10B+ quarterly private-markets raises would support the bull re-rating.
Thesis tripwires (what would change the call): two consecutive quarters of negative firm-wide long-term net flows (→ toward Avoid); a renewed Western Asset redemption wave; a market drawdown that shrinks AUM materially; or, on the upside, durable organic-inflow acceleration + fee-rate expansion (→ toward Buy — Tactical on a pullback).
11. Key risks
- Secular active-to-passive shift (structural): the core product is losing share to index funds/ETFs — a persistent, industry-wide headwind Franklin cannot fully offset.
- Flow/key-person fragility: the Western Asset episode showed how fast active AUM can leave; −$4.1B still left Western in Q2 FY26.
- Market beta (cyclical): beta 1.59; revenue is a direct function of AUM, so a market drawdown compounds into earnings and the stock.
- Valuation-after-the-run: a 40% 12-month move to a 52-week high, RSI 70, price above the Street's high target — limited margin of safety for new money.
- GAAP vs adjusted gap / leverage: heavy intangible amortization, an impairment, and CIP consolidation make GAAP earnings and leverage look worse than the adjusted economics; the dividend's GAAP payout is high (~84%).
- No expert corroboration: zero KB coverage — this call rests only on quant/fundamentals, so treat conviction as low.
12. Verdict, position sizing & monitoring
Watch. Franklin is a legitimately cheap, 3.8%-yielding value/income name (~12× adjusted EPS) that has done the right things — stabilizing flows, pushing into alternatives and ETFs, delivering a clean Q2 adjusted beat ($0.71 vs $0.55). But it is a low-growth, structurally-pressured active manager (Growth 3/10, Exponential 2/10), and after a 40% run it now trades at its 52-week high, above the Street's consensus and even its high target, with RSI at 70. The upside to our ~$32 base fair value is negative from here; the value is in the dividend and the cheap multiple, not in appreciation. That is a Watch, not a Buy — and not an Avoid, because the valuation floor and yield provide real support.
- Sizing: if held for income, an income/value satellite of ≤1–2%, ideally entered on a pullback toward the ~$31 50-DMA, not at the 52-week high. Not a core compounder.
- Monitoring: re-score on the §10 tripwires; the decisive variable is firm-wide long-term net flows each quarter (and Western specifically). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $34.11.
- Single biggest risk: secular active outflows resuming — the entire model is a leveraged bet on the fee base, and the fee base is under permanent competitive pressure.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of BEN in the Synthos knowledge base, so §2 cites nothing and the verdict is explicitly fundamentals-/quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation); here there simply are no claims to cite.
- Data as-of: fundamentals 2026-03-31 (Q2 FY26) · estimates & prices 2026-07-02/03 · SEC 8-K earnings release 2026-04-28. Forward figures are analyst consensus (FMP) or Synthos scenario estimates, labeled as estimates.
- Adjusted vs GAAP: valuation uses adjusted EPS (~$2.80 annualized), management's non-GAAP measure, because GAAP is distorted by intangible amortization/impairment and consolidated-investment-product accounting; both figures are shown so readers can judge the gap.
- Management caveat: the Q2 FY26 CEO commentary is management's own, self-interested characterization (half-weighted); Franklin issues no formal forward guidance.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").